Shots:

• Inflammasome to receive up to $160M up front- R&D milestone- commercialization milestone with royalties on sales of the developed product. The companies will co-develop up to three therapies for patients with retinal disease
• The focus of the agreement is to strengthen Boehringer’s retinal portfolio by combining with Inflammasome’s IVT drug delivery technology. The collaboration will lead to the reduction in eye disease by delivering biodegradable gel therapies into the eye
• Boehringer has a pipeline of ophthalmology developing next-generation therapies progressed up to P-II stage targeted for macular degeneration- diabetic retinal diseases and beyond- utilizing Inflammasome’s IVT implants to complement its portfolio

Click here to­ read full press release/ article | Ref: Boehringer Ingelheim | Image: Space well Interiors